Evidence mapPaperPMID 39385390Full record

ReviewJournal of inherited metabolic disease2024

Disease models of Leigh syndrome: From yeast to organoids.

Marie-Thérèse Henke, Alessandro Prigione, Markus Schuelke

Abstract readReview
In one paragraph

Review in Journal of inherited metabolic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Mitochondrial complex I deficiency-associated diseases and models.Cellular and molecular life sciences : CMLS · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Animal Models of Human Disease 2.0.International journal of molecular sciences · 2024
    Article
  9. Disease models of Leigh syndrome: From yeast to organoids.Journal of inherited metabolic disease · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Marie-Thérèse HenkeNeuroCure Cluster of Excellence, Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0001-6572-1667
Alessandro PrigioneDepartment of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany.ORCID 0000-0001-9457-1952
Markus SchuelkeNeuroCure Cluster of Excellence, Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0003-2824-3891

Funding

DFG (Deutsche Forschungsgemeinschaft) PR1527/6-1DFG (Deutsche Forschungsgemeinschaft) under Germany's Excellence Strategy EXC-2049-390688087European Joint Programme for Rare Diseases (EJPRD) supported in Germany by the BMBF (Bundesministerium für Bildung und Forschung) 01GM2002AFondation Maladies RaresFoundations MitoHelp, CureMito, and CureATP6HORIZON EUROPE European Research Council 101080249
6 · The paper itself

Abstract

Leigh syndrome (LS) is a severe mitochondrial disease that results from mutations in the nuclear or mitochondrial DNA that impairs cellular respiration and ATP production. Mutations in more than 100 genes have been demonstrated to cause LS. The disease most commonly affects brain development and function, resulting in cognitive and motor impairment. The underlying pathogenesis is challenging to ascertain due to the diverse range of symptoms exhibited by affected individuals and the variability in prognosis. To understand the disease mechanisms of different LS-causing mutations and to find a suitable treatment, several different model systems have been developed over the last 30 years. This review summarizes the established disease models of LS and their key findings. Smaller organisms such as yeast have been used to study the biochemical properties of causative mutations. Drosophila melanogaster, Danio rerio, and Caenorhabditis elegans have been used to dissect the pathophysiology of the neurological and motor symptoms of LS. Mammalian models, including the widely used Ndufs4 knockout mouse model of complex I deficiency, have been used to study the developmental, cognitive, and motor functions associated with the disease. Finally, cellular models of LS range from immortalized cell lines and trans-mitochondrial cybrids to more recent model systems such as patient-derived induced pluripotent stem cells (iPSCs). In particular, iPSCs now allow studying the effects of LS mutations in specialized human cells, including neurons, cardiomyocytes, and even three-dimensional organoids. These latter models open the possibility of developing high-throughput drug screens and personalized treatments based on defined disease characteristics captured in the context of a defined cell type. By analyzing all these different model systems, this review aims to provide an overview of past and present means to elucidate the complex pathology of LS. We conclude that each approach is valid for answering specific research questions regarding LS, and that their complementary use could be instrumental in finding treatment solutions for this severe and currently untreatable disease.

Indexed as

Disease Models, AnimalLeigh DiseaseOrganoidsAnimalsCaenorhabditis elegansDrosophila melanogasterElectron Transport Complex IHumansInduced Pluripotent Stem CellsMiceMitochondriaMutationZebrafishElectron Transport Complex Ianimal modelsdisease modelingLeigh syndromemitochondrial diseasesorganoidsphenotypingpluripotent stem cells

Identifiers

PMID39385390
PMCPMC11586605

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.